Symmetric Polyoxometalate Clusters Mediate Hierarchical Chirality Amplification into Macroscopic HelicesAdvanced Functional MaterialsIF192026-01-220PRE
Single-cell RNA sequencing reveals immune response dynamics and infection mechanisms in PRRSV-infected porcine alveolar macrophages单细胞RNA测序揭示了PRRSV感染猪肺泡巨噬细胞中的免疫应答动态和感染机制International Journal of Biological MacromoleculesIF8.52025-11-030PRE
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX studyCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32024-04-152OAAI
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findingsADVANCED DRUG DELIVERY REVIEWSIF17.62024-04-011OAAI
gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolveCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32023-12-262OAAI
Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphomaFRONTIERS IN IMMUNOLOGYIF5.92023-03-293OAAI
Expression and Characterization of 3,6-Dihydroxy-picolinic Acid Decarboxylase PicC of Bordetella bronchiseptica RB50MICROORGANISMSIF4.22023-03-271OAAI
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitisCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32022-07-293OA
Amelioration of Beta Interferon Inhibition by NS4B Contributes to Attenuating Tembusu Virus Virulence in DucksFRONTIERS IN IMMUNOLOGYIF5.92021-05-179OAAI
Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based EvaluationJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72021-04-016OAAI
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin LymphomaPHARMACEUTICAL RESEARCHIF4.32020-12-019OAAI
Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric ModelsCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32020-01-3010OAAI
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin LymphomaCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32019-12-2330OAAI
RETRACTED: MicroRNA-217 relieved neuropathic pain through targeting toll-like receptor 5 expression (Retracted article. See vol. 123, pg. 989, 2022)JOURNAL OF CELLULAR BIOCHEMISTRYIF2.82018-12-1112PREAI
Characterization and Genome Analysis of a Nicotine and Nicotinic Acid-Degrading Strain Pseudomonas putida JQ581 Isolated from MarineMARINE DRUGSIF5.42017-05-3123OAAI
Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate.MOLECULAR CANCER THERAPEUTICSIF5.52013-11-011PRE
Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population ApproachINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCEIF4.72013-03-05174PREAI
Determination of limonin in rat plasma by liquid chromatography-electrospray mass spectrometryJOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSISIF3.12005-10-0121PREAI